A AutoLab
Equities / Lumibird (EPA: LBIRD)

Lumibird

European laser group; defense + space +20%, photonics div +14%; FY2025 +9% with margin expansion

EPA: LBIRD Laser / photonics France 2026-06-01 0.58MODERATE
Download PDF Infographic (PNG)

Snapshot

  • TickerEPA: LBIRD
  • Price~€8.5 (May-2026)
  • Market cap~€185m
  • Revenue€225.6m FY2025 (+8.9% reported, +10.2% at constant scope and FX) [S1][S2]
  • GrowthPhotonics +14% (Defense + Space +20%); Medical +4% — strong defense / space driver [S1]
  • ProfitabilityEBITDA €45.6m FY2025 (+38% YoY, 20.2% of revenue) [S1]
  • Valuation~0.8× P/S, ~4× EV/EBITDA — deep value if margins durable
  • Whatlaser technology — Photonics (industrial, scientific, defense, space) and Medical (ophthalmic, aesthetic) lasers; result of 2017 Keopsys–Quantel merger
  • End marketsdefense (LiDAR, missile guidance, range-finding), space (satellite payloads), industrial (semicap), scientific research, ophthalmology, aesthetic dermatology
  • VerdictDeep-value European laser group; defense / space tailwind is real but the consolidated business is still small and mid-cycle
  • Confidence0.58

Financial analysis

EUR mFY2023FY2024FY2025
Revenue~204207.1 (+1.7%)225.6 (+8.9% YoY; +10.2% LFL)
EBITDAn/d32.9 (15.9% margin)45.6 (20.2% margin, +38% YoY)
Photonics revenuen/d99.4 (−1.4%)113.4 (+14%)
Medical revenuen/d~108~112 (+4%)

Source: [S1][S2]. The FY2025 EBITDA-margin expansion (16% → 20%) is the central bull-case signal; durability is the open question.

Executive summary

Lumibird is the European leader in laser technologies — the result of the 2017 merger between Keopsys (fiber lasers) and Quantel (solid-state + medical lasers). FY2025 delivered the most encouraging set of results since the merger: revenue €225.6m (+9% reported, +10% LFL), EBITDA €45.6m (+38% YoY, 20% of revenue), driven by a Photonics division +14% with Defense + Space within it up +20% [S1][S2]. The European defense budget reflation (post-Ukraine, post-2025) plus space-payload demand are the two structural tailwinds. The Medical division (~50% of revenue, +4%) is steadier but lower-growth. At ~€185m market cap on €225m revenue, the stock trades at ~0.8× sales and ~4× EV/EBITDA — deep-value territory if the FY2025 margin expansion proves durable. The catch: the company is small relative to Coherent / IPG / Trumpf, and historical execution has been uneven.

Verdict: Deep-value European laser group; defense + space tailwind real but execution history is uneven. Confidence: 0.58

Headwinds & key risks

  • Small absolute scale (~€225m revenue) makes Lumibird sub-scale vs Coherent / IPG / Trumpf — pricing power limited in non-defense end markets.
  • Margin volatility — FY2025’s 20% EBITDA margin is a recovery off lower years; durability is the open question.
  • Medical division growth is slow (+4%); if Photonics decelerates the group falls back to single-digit growth.
  • Defense budget reflation is a real tailwind but tied to multi-year political cycles; reversion to mean is possible.
  • Multi-site integration (Keopsys-Quantel merger + later bolt-ons) carries operational complexity not yet visible in the segment reporting.

Verdict & what to watch

Lumibird is a deep-value European laser group with a real defense / space tailwind and improving margins. The setup is interesting (cheap + margin-expanding + defense exposure) but the business is small and the execution history is uneven. Confidence: 0.58 — basket-worthy on valuation + theme; not an asymmetric bet on its own.

Decision boundaries

  • (+) If FY2026 EBITDA margin holds ≥18% (i.e. proven durable, not a one-off) → conviction rises by ~0.10.
  • (+) If Defense + Space disclosed as ≥30% of revenue with ≥15% YoY growth → conviction rises by ~0.10.
  • (+) If a strategic acquirer or PE buyout emerges at a premium (deep-value setup attracting consolidators) → event-driven.
  • (−) If FY2026 revenue growth decelerates below +5% LFL → conviction drops by ~0.10.
  • (−) If EBITDA margin falls back below 15% → conviction drops by ~0.10 (margin expansion was the bull anchor).

Open questions

  • [confidence: 0.3] Defense + Space share of revenue and named programs — would need a T1 source: the annual report / capital-markets day.
  • [confidence: 0.3] Photonics vs Medical segment margin split — would need a T1 source: full annual report segment table.

Sources

Doctrine: see /principles. This file is scaffold-with-Snapshot — a full long-form pass via autolab refresh is pending and is the source of the needs_refresh: true flag.